South Korea-based SN BioScience announced on Thursday that it has entered into a domestic manufacturing technology transfer and co-development contract with Boryeong, a pharmaceutical company in Korea, for the albumin nanoparticle anticancer drug (code name: SNA-001), a generic version of Abraxane.
SNA-001 has been developed by SN BioScience for the first time in Korea and the fourth time in the world. It is a product that electrostatically binds cytotoxic anticancer drugs to albumin utilising albumin present in human blood as a drug carrier. Abraxane is a global blockbuster first developed by Abraxis BioScience Inc (acquired by Celgene who became a subsidiary of BMS), with sales of USD1.5bn worldwide in 2020.
The contract allows Boryeong to have exclusive manufacturing and distribution rights in Korea for SNA-001. SN BioScience is to receive milestones and double-digit royalties based on the development stage.
Accord Healthcare launches Lurasidone HCL tablets
US FDA Accepts the ATI-1501 NDA, According to Appili Therapeutics
Sanofi reports Q4 sales of Dupixent up 42%
Upsher-Smith Laboratories launches Fluoxetine Oral Solution, USP, 20mg/5mL
Astellas Pharma enters into Asset Purchase Agreement with Sandoz
ANI Pharmaceuticals Launches Levocarnitine Tablets USP Following US FDA Approval
Hartness Named to Bryn Pharma Board of Directors
Accord Healthcare adds Bendamustine Lyo. Injection to range of chemotherapy drugs
ANI Pharmaceuticals Receives FDA Approval, Launches Fluoxetine Oral Solution USP
ANI Pharmaceuticals receives FDA approval for Fluoxetine Oral Solution USP
Prasco Laboratories introduces Authorised Generic of ZIOPTAN in partnership with Thea Pharma
ANI Pharmaceuticals declares FDA approval and commercialisation of Trimethoprim Tablets USP
McKinley, Boothe Named to Maxwell Biosciences Board of Directors